Premium
Schizophrenia and neurotrophin‐3 alleles
Author(s) -
Jönsson E.,
Brené S.,
Zhang X. R.,
Nimgaonkar V. L.,
Tylec A.,
Schalling M.,
Sedvall G.
Publication year - 1997
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1997.tb09654.x
Subject(s) - allele , schizophrenia (object oriented programming) , polymorphism (computer science) , neurotrophin 3 , allele frequency , brain derived neurotrophic factor , psychosis , neurotrophin , genetics , medicine , neurotrophic factors , psychology , psychiatry , biology , gene , receptor
Studies of brain anatomy and premorbid functioning indicate that schizophrenia may be of neurodevelopmental origin. In the neurotrophic factor neurotrophin‐3 (NT‐3) gene, the A3/147‐bp allele in a dinucleotide repeat polymorphism located in the promoter region was found to be associated with schizophrenia in a Japanese study. Another NT‐3 polymorphism (Glu63Gly) indicated an association with schizophrenic patients with a putative neurodevelopmental form of the disease. We examined Swedish schizophrenic patients ( n =109) and control subjects ( n =78) for the same two NT‐3 polymorphisms, as well as a third silent exonic polymorphism (at Pro55). No significant difference was found between the two groups. However, in a meta‐analysis including the present and previous studies of Caucasian subjects, the A3/147‐bp allele frequency was found to be significantly higher in the schizophrenic patients. In the present study, carriers of the A3/147 bp allele tended to have an earlier age of onset and to display more extrapyramidal symptoms. In the silent exonic polymorphism (at Pro55), female schizophrenic patients had higher adenine and lower guanine allele frequencies than control female subjects. Together with previous studies, the results provide some support for an association between the NT‐3 gene and certain forms of schizophrenia. This warrants further investigation of NT‐3 and other neurotrophic factors with additional polymorphisms and larger patient samples.